Search

Your search keyword '"Daniels, Laurien"' showing total 34 results
Start Over Author "Daniels, Laurien"
34 results on '"Daniels, Laurien"'

1. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Author

Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2024
Full Text
View/download PDF

2. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

Author

Starreveld, Daniëlle EJ, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus JW, Habers, G Esther A, Bosch, Jos A, Janus, Cécile PM, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik WA, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline MA

Subjects
cancer-related fatigue, circadian rhythms, light therapy, randomized controlled trial, sleep, Clinical Research, Depression, Rehabilitation, Rare Diseases, Lymphoma, Cancer, Clinical Trials and Supportive Activities, Behavioral and Social Science, Sleep Research, Hematology, Mental Health, Oncology and Carcinogenesis
Abstract

PurposeTo evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.MethodsWe randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.ResultsThere were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.ConclusionsBWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

3. Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial

Author

Starreveld, Daniëlle EJ, Daniels, Laurien A, Valdimarsdottir, Heiddis B, Redd, William H, de Geus, Jessie L, Ancoli-Israel, Sonia, Lutgendorf, Susan, Korse, Catharina M, Kieffer, Jacobien M, van Leeuwen, Flora E, and Bleiker, Eveline MA

Subjects
Biomedical and Clinical Sciences, Health Services and Systems, Nursing, Health Sciences, Oncology and Carcinogenesis, Rare Diseases, Behavioral and Social Science, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Prevention, Sleep Research, Cancer, Lymphoma, Evaluation of treatments and therapeutic interventions, 6.6 Psychological and behavioural, Cancer Survivors, Clinical Protocols, Disease Management, Fatigue, Female, Hodgkin Disease, Humans, Male, Multicenter Studies as Topic, Phototherapy, Randomized Controlled Trials as Topic, Cancer related fatigue, Light therapy, Sleep quality, Randomized controlled trial, Circadian rhythms, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundCancer related fatigue (CRF) is one of the most prevalent and distressing long-term complaints reported by (non-) Hodgkin survivors. To date there has been no standard treatment for CRF in this population. A novel and promising approach to treat CRF is exposure to bright white light therapy. Yet, large scale randomized controlled trials testing its efficacy in these patients and research on potential mechanisms is lacking. The objective of the current study is to investigate the efficacy of light therapy as a treatment for CRF and to explore potential mechanisms.Methods/designIn a multicenter, randomized controlled trial we are evaluating the efficacy of two intensities of light therapy in reducing CRF complaints and restrictions caused by CRF in survivors of Hodgkin lymphoma or diffuse large B-cell lymphoma. Secondary outcomes include sleep quality, depression, anxiety, quality of life, cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian rhythms of melatonin, cortisol and activity, and biomarkers of inflammation. We will recruit 128 survivors, with fatigue complaints, from academic and general hospitals. Survivors are randomized to either an intervention (exposure to bright white light) or a comparison group (exposure to dim white light). The longitudinal design includes four measurement points at baseline (T0), post-intervention at 3.5 weeks (T1), 3 months post-intervention (T2) and 9 months post-intervention (T3). Each measurement point includes self-reported questionnaires and actigraphy (10 days). T0 and T1 measurements also include collection of blood and saliva samples.DiscussionLight therapy has the potential to be an effective treatment for CRF in cancer survivors. This study will provide insights on its efficacy and potential mechanisms. If proven to be effective, light therapy will provide an easy to deliver, low-cost and low-burden intervention, introducing a new era in the treatment of CRF.Trial registrationThe study is registered at ClinicalTrials.gov on August 8th 2017( NCT03242902 ).

Published
2018

4. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Author

Chua, Boon H, Phillips, Claire, Bryant, Guy, Westenberg, Helen, Purohit, Om Pra-Kesh, Ahern, Verity, Graham, Peter, Akra, Mohamed, McArdle, Orla, O'Brien, Peter, Ludbrook, Jane, Harvey, Jennifer, Maduro, John H, Gabelle-Flandin, Isabelle, Kirkove, Carine, Bedi, Carolyn, Martin, Joseph, Vu, Tony, Muanza, Theirry, Neal, Anthony, Courdi, Adel, Thariat, Juliette, Rakovitch, Eileen, Daniels, Laurien, van Hezewijk, Marjan, Cwajna, Wlasyslawa, Roelstraete, Adelheid, van Baardwijk, Angela, Russel, Nicola, Koch, Anne, Croke, Jennifer, Locke, Imogen, Jeal, Peter, Walker, Quenten, Thuraisingham, Kandeepeepan, Chauduri, Anupam, Joseph, David, Taylor, Mandy, Vanderkam, Sabine, Woo, Tony, Tang, Johann, Yassa, Michael, Wai, Elaine, Hewitt, Susan, Mahmood, Shazia, Gilmore, Jennifer, Ofi, Bolante, Bahl, Amit, Vujovic, Olga, Yu, Edward, Le, Duc, Kong, Iwa, Nichol, Alan, Bijker, Nina, Delaney, Geoff, Feigen, Malcolm, Lim, Adeline, Chao, Michael, Latham, Margaret, Algurafi, Hafiz, Tausch, Christoph, Khoo, Eric, Leung, Sam, Taylor, Karen, Senthi, Sasha, Stevens, Andrea, Chaudhuri, Abhro, Cleator, Susan, Brunt, Adrian Murray, Babington, Scott, Christie, David, Zwahlen, Daniel, Schratzenstaller, Ulrich, Masson, Laurence, Storey, Nicola, Kumar, Eshwar, Sherwin, Liz, Weytjens, Reinhilde, Ravi, Sharma, Lawton, Patricia, Angell, Ruth, Round, Glenys, Allen, Angela, Thotathil, Ziad, Anthes, Margaret, Reuter, Christiane, Pettit, Laura, Zissiadis, Yvonne, Elder, Christine, Verbeek-de Kanter, Antoinette, Lirette, Andree, Plasswilm, Ludwig, Spooner, David, Hoar, Fiona, Mohamed, Islam, Lossl, Kristina, Loo, Vivienne, Richetti, Antonella, Evans, Tamasin, Hennessy, Aisling, El-Mallah, Medhat, Skala, Marketa, Awad, Raef, Germain, Isabelle, Mitine, Carine, Van Parijs, Hilde, Churn, Mark, Walji, Nawaz, Francis, Michael, Stellamans, Karin, Gruber, Gunther, Ivaldi, Giovanni, Alhasso, Abdulla, Kenny, Lizbeth, Tiver, Ken, Griffin, Matthew, Lamoury, Gillian, Trovo, Marco, Algufarfi, Hafiz, Lah, Minjae, Carruthers, Scott, Papadatos, George, Paardekooper, Gabriel, Persic, Mojca, Lavery, Bernadette, King, Madeleine T, Link, Emma K, Whelan, Tim J, Olivotto, Ivo A, Kunkler, Ian, Westenberg, Antonia Helen, Gruber, Guenther, and Schofield, Penny

Published
2020
Full Text
View/download PDF

5. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Author

MS Radiotherapie, Cancer, Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., Vis, André N., MS Radiotherapie, Cancer, Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2024

6. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high-and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

Author

EORTC Quality of Life Group, van de Poll-Franse, Lonneke, Oerlemans, Simone, Bredart, Anne, Kyriakou, Charalampia, Sztankay, Monika, Pallua, Stephan, Daniëls, Laurien, Creutzberg, Carien L., Cocks, Kim, Malak, Sandra, Caocci, Giovanni, Molica, Stefano, Chie, Weichu, and Efficace, Fabio

Published
2018

11. Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring

Author

Schrader, Anne M. R., primary, de Groen, Ruben A. L., additional, Willemze, Rein, additional, Jansen, Patty M., additional, Quint, Koen D., additional, Cleven, Arjen H. G., additional, van Wezel, Tom, additional, van Eijk, Ronald, additional, Ruano, Dina, additional, Veelken, J. H. (Hendrik), additional, Tensen, Cornelis P., additional, Neelis, Karen J., additional, Daniels, Laurien A., additional, Hauben, Esther, additional, Woei-A-Jin, F. J. S. H. (Sherida), additional, Busschots, A. M. (Annemie), additional, Vermeer, Maarten H., additional, and Vermaat, Joost S. P., additional

Published
2022
Full Text
View/download PDF

12. P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

Author

Mieras, Adinda, primary, Nijdam, Annelies, additional, Aleman, Berthe M. P., additional, Daniels, Laurien, additional, De Jongh, Eva, additional, Janus, Cécile P.M., additional, Krol, Stijn, additional, Ta, Bastiaan D.P., additional, Ong, Francisca, additional, Van Spronsen, Dick Johan, additional, Posthuma, Ward, additional, Plattel, Wouter J., additional, Oostvogels, Rimke, additional, Verschueren, Karijn, additional, Zijlstra, Josée. M., additional, and Van Leeuwen, Flora E., additional

Published
2022
Full Text
View/download PDF

14. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer

Author

MS Radiotherapie, Cancer, Meijer, Dennie, Eppinga, Wietse S.C., Mohede, Roos M., Vanneste, Ben G.L., Meijnen, Philip, Meijer, Otto W.M., Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Ettema, Rosemarijn H., Oudshoorn, Frederik H.K., van Leeuwen, Pim J., van der Poel, Henk G., Donswijk, Maarten L., Oprea-Lager, Daniela E., Schaake, Eva E., Vis, André N., MS Radiotherapie, Cancer, Meijer, Dennie, Eppinga, Wietse S.C., Mohede, Roos M., Vanneste, Ben G.L., Meijnen, Philip, Meijer, Otto W.M., Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Ettema, Rosemarijn H., Oudshoorn, Frederik H.K., van Leeuwen, Pim J., van der Poel, Henk G., Donswijk, Maarten L., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2022

15. PD22-02 RESTAGING PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IS ASSOCIATED WITH IMPROVED ONCOLOGICAL OUTCOME IN MEN WHO UNDERWENT SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER

Author

Meijer, Dennie, primary, Eppinga, Wietse, additional, Mohede, Roos, additional, Vanneste, Ben, additional, Meijnen, Philip, additional, Meijer, Otto, additional, Daniels, Laurien, additional, Van den Bergh, Roderick, additional, Lont, Anne, additional, Ettema, Rosemarijn, additional, Oudshoorn, Frederik, additional, van Leeuwen, Pim, additional, Van der Poel, Henk, additional, Donswijk, Maarten, additional, Oprea-Lager, Daniela, additional, Schaake, Eva, additional, and Vis, André, additional

Published
2022
Full Text
View/download PDF

16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer

Author

Meijer, Dennie, primary, Eppinga, Wietse S.C., additional, Mohede, Roos M., additional, Vanneste, Ben G.L., additional, Meijnen, Philip, additional, Meijer, Otto W.M., additional, Daniels, Laurien A., additional, van den Bergh, Roderick C.N., additional, Lont, Anne P., additional, Ettema, Rosemarijn H., additional, Oudshoorn, Frederik H.K., additional, van Leeuwen, Pim J., additional, van der Poel, Henk G., additional, Donswijk, Maarten L., additional, Oprea-Lager, Daniela E., additional, Schaake, Eva E., additional, and Vis, André N., additional

Published
2022
Full Text
View/download PDF

19. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial

Author

Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, Bleiker, Eveline M A, Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline M A

Abstract

PURPOSE: To evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.METHODS: We randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.RESULTS: There were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.CONCLUSIONS: BWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

20. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors:Results of a Randomized Controlled Trial

Author

Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, Bleiker, Eveline M A, Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline M A

Abstract

PURPOSE: To evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.METHODS: We randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.RESULTS: There were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.CONCLUSIONS: BWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

21. A Baseline Survey on the Treatment Workflow and Pediatric IGRT Practice Among European Members of the Project-Based Consortium and the Pediatric Radiation Oncology Society (PROS).

Author

Windmeijer, Coen A.A., primary, Bel, Arjan, additional, Jong, Rianne de, additional, Balgobind, Brian V., additional, Aznar, Marianne C., additional, Beek, Karen van, additional, Beldjoudi, Guillaume, additional, Boterberg, Tom, additional, Cernea, Dana M., additional, Daniels, Laurien, additional, Dieckmann, Karin, additional, Filippi, Andrea R., additional, Haasbeek, Cornelis J.A., additional, Hoeben, Bianca, additional, Janssens, Geert O.R., additional, Josipovic, Mirjana, additional, Jürgens, Hannes, additional, Kouvelis, Adam, additional, Lassen, Yasmin, additional, Loginova, Anna, additional, Maduro, John H., additional, Ondrová, Barbora, additional, Rombi, Barbara, additional, Steinmann, Diana, additional, Stokkevag, Camilla, additional, Theodorou, Marilena, additional, Timmermann, Beate, additional, Vasileva-Kodeyh, Vaska, additional, Zaletel, Lorna Zadravec, additional, and Dijk, Irma W.E.M. van, additional

Published
2020
Full Text
View/download PDF

22. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Author

King, Madeleine T, primary, Link, Emma K, additional, Whelan, Tim J, additional, Olivotto, Ivo A, additional, Kunkler, Ian, additional, Westenberg, Antonia Helen, additional, Gruber, Guenther, additional, Schofield, Penny, additional, Chua, Boon H, additional, Phillips, Claire, additional, Bryant, Guy, additional, Westenberg, Helen, additional, Purohit, Om Pra-Kesh, additional, Ahern, Verity, additional, Graham, Peter, additional, Akra, Mohamed, additional, McArdle, Orla, additional, O'Brien, Peter, additional, Ludbrook, Jane, additional, Harvey, Jennifer, additional, Maduro, John H, additional, Gabelle-Flandin, Isabelle, additional, Kirkove, Carine, additional, Bedi, Carolyn, additional, Martin, Joseph, additional, Vu, Tony, additional, Muanza, Theirry, additional, Neal, Anthony, additional, Courdi, Adel, additional, Thariat, Juliette, additional, Rakovitch, Eileen, additional, Daniels, Laurien, additional, van Hezewijk, Marjan, additional, Cwajna, Wlasyslawa, additional, Roelstraete, Adelheid, additional, van Baardwijk, Angela, additional, Russel, Nicola, additional, Koch, Anne, additional, Croke, Jennifer, additional, Locke, Imogen, additional, Jeal, Peter, additional, Walker, Quenten, additional, Thuraisingham, Kandeepeepan, additional, Chauduri, Anupam, additional, Joseph, David, additional, Taylor, Mandy, additional, Vanderkam, Sabine, additional, Woo, Tony, additional, Tang, Johann, additional, Yassa, Michael, additional, Wai, Elaine, additional, Hewitt, Susan, additional, Mahmood, Shazia, additional, Gilmore, Jennifer, additional, Ofi, Bolante, additional, Bahl, Amit, additional, Vujovic, Olga, additional, Yu, Edward, additional, Le, Duc, additional, Kong, Iwa, additional, Nichol, Alan, additional, Bijker, Nina, additional, Delaney, Geoff, additional, Feigen, Malcolm, additional, Lim, Adeline, additional, Chao, Michael, additional, Latham, Margaret, additional, Algurafi, Hafiz, additional, Tausch, Christoph, additional, Khoo, Eric, additional, Leung, Sam, additional, Taylor, Karen, additional, Senthi, Sasha, additional, Stevens, Andrea, additional, Chaudhuri, Abhro, additional, Cleator, Susan, additional, Brunt, Adrian Murray, additional, Babington, Scott, additional, Christie, David, additional, Zwahlen, Daniel, additional, Schratzenstaller, Ulrich, additional, Masson, Laurence, additional, Storey, Nicola, additional, Kumar, Eshwar, additional, Sherwin, Liz, additional, Weytjens, Reinhilde, additional, Ravi, Sharma, additional, Lawton, Patricia, additional, Angell, Ruth, additional, Round, Glenys, additional, Allen, Angela, additional, Thotathil, Ziad, additional, Anthes, Margaret, additional, Reuter, Christiane, additional, Pettit, Laura, additional, Zissiadis, Yvonne, additional, Elder, Christine, additional, Verbeek-de Kanter, Antoinette, additional, Lirette, Andree, additional, Plasswilm, Ludwig, additional, Spooner, David, additional, Hoar, Fiona, additional, Mohamed, Islam, additional, Lossl, Kristina, additional, Loo, Vivienne, additional, Richetti, Antonella, additional, Evans, Tamasin, additional, Hennessy, Aisling, additional, El-Mallah, Medhat, additional, Skala, Marketa, additional, Awad, Raef, additional, Germain, Isabelle, additional, Mitine, Carine, additional, Van Parijs, Hilde, additional, Churn, Mark, additional, Walji, Nawaz, additional, Francis, Michael, additional, Stellamans, Karin, additional, Gruber, Gunther, additional, Ivaldi, Giovanni, additional, Alhasso, Abdulla, additional, Kenny, Lizbeth, additional, Tiver, Ken, additional, Griffin, Matthew, additional, Lamoury, Gillian, additional, Trovo, Marco, additional, Algufarfi, Hafiz, additional, Lah, Minjae, additional, Carruthers, Scott, additional, Papadatos, George, additional, Paardekooper, Gabriel, additional, Persic, Mojca, additional, and Lavery, Bernadette, additional

Published
2020
Full Text
View/download PDF

23. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort : Contributions of radiation dose, exposed cranial volume, and age

Author

Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, and DCOG-LATER Study Group

Subjects
Cancer Research, Oncology, childhood cancer survivors, Clinical Neurology, cranial radiotherapy, radiation volume, radiation dose, meningioma
Abstract

Background. Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed cranial volume, exposure age, and chemotherapy. Methods. The Dutch Cancer Oncology Group-Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort includes 5-year childhood cancer survivors (CCSs) whose cancers were diagnosed in 1963-2001. Histologically confirmed benign meningiomas were identified from the population-based Dutch Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used multivariable Cox regression and linear excess relative risk (ERR) modeling. Results. Among 5843 CCSs (median follow-up: 23.3 y, range: 5.0-52.2 y), 97 developed a benign meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared with CrRT doses of 1-19 Gy, no CrRT was associated with a low meningioma risk (hazard ratio [HR] = 0.04, 95% CI: 0.01-0.15), while increased risks were observed for CrRT doses of 20-39 Gy (HR = 1.66, 95% CI: 0.83-3.33) and 40+ Gy (HR = 2.81, 95% CI: 1.30-6.08). CCSs whose cancers were diagnosed before age 5 versus 10-17 years showed significantly increased risks (HR = 2.38, 95% CI: 1.39-4.07). In this dose-adjusted model, volume was not significantly associated with increased risk (HR full vs partial = 1.66, 95% CI: 0.86-3.22). Overall, the ERR/Gy was 0.30 (95% CI: 0.03-unknown). Dose effects did not vary significantly according to exposure age or CrRT volume. Cumulative incidence after any CrRT was 12.4% (95% CI: 9.8%-15.2%) 40 years after primary cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only carboplatin (HR = 3.55, 95% CI: 1.62-7.78) appeared associated with meningioma risk. However, we saw no carboplatin dose-response and all 9 exposed cases had high-dose CrRT. Conclusion. After CrRT 1 in 8 survivors developed late meningioma by age 40 years, associated with radiation dose and exposure age, relevant for future treatment protocols and awareness among survivors and physicians.

Published
2019

24. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease

Author

Melchers, R.C., Willemze, R., Vermaat, J.S., Jansen, P.M., Daniels, Laurien A., Putter, H., Bekkenk, M.W., Haas, E.R. de, Horvath, B., Rossum, M.M. van, Sanders, C.J., Veraart, J., Vermeer, M.H., Quint, K.D., Melchers, R.C., Willemze, R., Vermaat, J.S., Jansen, P.M., Daniels, Laurien A., Putter, H., Bekkenk, M.W., Haas, E.R. de, Horvath, B., Rossum, M.M. van, Sanders, C.J., Veraart, J., Vermeer, M.H., and Quint, K.D.

Abstract

Contains fulltext : 218224.pdf (Publisher’s version ) (Open Access)

Published
2020

25. Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma

Author

Nijdam, A., Dekker, N., Aleman, B.M.P., Veer, M.B. van 't, Daniels, Laurien A., Maazen, R.W.M. van der, Janus, C.P., Weijer, R.J. de, Zijlstra, J.M., Stedema, F.G., Ta, B.D., Posthuma, E.F., Manenschijn, A., Dielwart, M.F., Bilgin, Y.M., Heuvel, M.J. van de, Boersma, R.S., Leeuwen, F.E. van, Raemaekers, J.M.M., Nijdam, A., Dekker, N., Aleman, B.M.P., Veer, M.B. van 't, Daniels, Laurien A., Maazen, R.W.M. van der, Janus, C.P., Weijer, R.J. de, Zijlstra, J.M., Stedema, F.G., Ta, B.D., Posthuma, E.F., Manenschijn, A., Dielwart, M.F., Bilgin, Y.M., Heuvel, M.J. van de, Boersma, R.S., Leeuwen, F.E. van, and Raemaekers, J.M.M.

Abstract

Contains fulltext : 208562.pdf (publisher's version ) (Closed access)

Published
2019

26. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: Contributions of radiation dose, exposed cranial volume, and age

Author

PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, MS Radiotherapie, Cancer, Klinische Fysica RT, Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, DCOG-LATER Study Group, PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, MS Radiotherapie, Cancer, Klinische Fysica RT, Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, and DCOG-LATER Study Group

Published
2019

27. First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Author

Meeuwes, Frederik O., Brink, Mirian, Van Der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-a-Jin, F.J. Sherida H., Visser, Otto J., Oostvogels, Rimke, Jansen, Patty M., Neelis, Karen J., Crijns, Anne P.G., Daniëls, Laurien A., Vermaat, Joost S.P., Huls, Gerwin A., and Nijland, Marcel

Published
2021
Full Text
View/download PDF

28. Cardiovascular disease risk after treatment-induced primary ovarian insufficiency in female survivors of Hodgkin lymphoma.

Author

Van Leeuwen, Flora, primary, Krul, Inge, additional, Opstal-Van Winden, Annemieke, additional, Janus, Cecile P.M., additional, Daniels, Laurien, additional, Maas, Angela, additional, Van Nimwegen, Rianne, additional, de Vries, Simone, additional, Hauptmann, Michael, additional, Józwiak, Katarzyna, additional, and Aleman, Berthe M.P., additional

Published
2018
Full Text
View/download PDF

29. Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma

Author

Krul, I.M., Opstal-van Winden, A.W.J., Janus, C.P., Daniels, Laurien A., Appelman, Y., Maas, A.H.E.M., Vries, S. de, Jozwiak, K., Aleman, B.M.P., Leeuwen, F.E. van, Krul, I.M., Opstal-van Winden, A.W.J., Janus, C.P., Daniels, Laurien A., Appelman, Y., Maas, A.H.E.M., Vries, S. de, Jozwiak, K., Aleman, B.M.P., and Leeuwen, F.E. van

Abstract

Item does not contain fulltext

Published
2018

30. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors

Author

Vries, S.E. de, Schaapveld, M., Nimwegen, F.A. van, Jozwiak, K., Lugtenburg, P.J., Daniels, Laurien A., Maazen, R.W.M. van der, Aleman, B.M.P., Leeuwen, Flora E., Vries, S.E. de, Schaapveld, M., Nimwegen, F.A. van, Jozwiak, K., Lugtenburg, P.J., Daniels, Laurien A., Maazen, R.W.M. van der, Aleman, B.M.P., and Leeuwen, Flora E.

Abstract

Contains fulltext : 190123.pdf (Publisher’s version ) (Open Access)

Published
2018

31. The BETER survivorship care initiative for Hodgkin lymphoma; Tailored survivorship care for late effects of treatment

Author

Dekker, Nicky, Van'T Veer, Mars B., Aleman, Berthe M.P., Van Leeuwen, Flora E., Raemaekers, John M.M., Schaapveld, Michael, Opstal-Van Winden, Annemieke, De Boer, Jan Paul, Sombroek, Cherita, Poortmans, Philip, Van Der Maazen, Richard, Lugtenburg, P. J.Elly, Janus, Cecile, Noordijk, Ed, Krol, A. D.G.Stijn, Daniels, Laurien, Zijlstra, Josée, Meijer, Otto, Petersen, Eefke, Buter, Denise, De Weijer, Roel, Roesink, Judith, Kluin-Nelemans, J. C.Hanneke, Van Imhoff, Gustaaf, De Vries, Floriske, Beijert, Max, Kersten, Marie José, Oldenburger, Foppe, Dieleman, Edith, Schouten, Harry, Borger, Jacques, Van De Voorde, Lien, Verschueren, Karijn, Schippers, Maaike, Verbeeten, Bernard, Ong, Francisca, Dorresteijn, Lucille, Schimmel, Erik, Bouma, Paul, Muller, Karin, Lybeert, Marnix, Dompeling, Ellen, Manenschijn, Annelies, Vos-Westerman, J. Hanneke, Van Kampen, Daphne, Dielwart, Michel, Posthuma, Ward, Böhmer, Lara, Te Boome, Liane, Visser, Hein, Epidemiology and Data Science, EMGO - Quality of care, Hematology, CCA - Imaging and biomarkers, CCA - Disease profiling, CCA - Imaging, Radiation Oncology, VU University medical center, and Oral and Maxillofacial Surgery / Oral Pathology

Subjects
humanities
Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of longterm Treatment Effects and screening Recommendations. The survivorship care focuses on longterm effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 19652008 have been identified. As part of the survivorship care initiative, specific BETER outpatient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Published
2016

32. Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.

Author

Nijdam, Annelies, Dekker, Nicky, Aleman, Berthe M. P., van 't Veer, Mars B., Daniels, Laurien A., Maazen, Richard W., Janus, Cecile P. M., Weijer, Roel J., Zijlstra, Josée M., Stedema, Floriske G., Ta, Bastiaan D., Posthuma, Eduardus F. M., Manenschijn, Annelies, Dielwart, Michel F. H., Bilgin, Yavuz M., Heuvel, Maaike J., Boersma, Rinske S., Leeuwen, Flora E., and Raemaekers, John M. M.

Subjects
HODGKIN'S disease, CANCER patients, ADVERSE health care events, GUIDELINES, MEDICAL care, HEALTH programs
Abstract

The article discusses the creation of a national program for Hodgkin lymphoma (HL) survivorship care in the Netherlands as of August 2019. Topics covered include the steps in screening of late adverse events like cardiovascular disease, thyroid dysfunction, and reduced fertility, the development of guidelines for the most frequent ones, and the flow of data from and to various sources and their use. Also noted are the BETER clinics' coordination with the patients' general practitioners (GP).

Published
2019
Full Text
View/download PDF

34. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.

Author

Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, van Rij C, Tersteeg RJHA, Hauptmann M, Kremer LCM, and Ronckers CM

Subjects
Adolescent, Adult, Age Factors, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Netherlands epidemiology, Organs at Risk, Proportional Hazards Models, Risk, Young Adult, Cancer Survivors, Cranial Irradiation, Meningeal Neoplasms epidemiology, Meningioma epidemiology, Neoplasms therapy, Neoplasms, Radiation-Induced epidemiology, Radiation Dosage
Abstract

Background: Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed cranial volume, exposure age, and chemotherapy., Methods: The Dutch Cancer Oncology Group-Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort includes 5-year childhood cancer survivors (CCSs) whose cancers were diagnosed in 1963-2001. Histologically confirmed benign meningiomas were identified from the population-based Dutch Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used multivariable Cox regression and linear excess relative risk (ERR) modeling., Results: Among 5843 CCSs (median follow-up: 23.3 y, range: 5.0-52.2 y), 97 developed a benign meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared with CrRT doses of 1-19 Gy, no CrRT was associated with a low meningioma risk (hazard ratio [HR] = 0.04, 95% CI: 0.01-0.15), while increased risks were observed for CrRT doses of 20-39 Gy (HR = 1.66, 95% CI: 0.83-3.33) and 40+ Gy (HR = 2.81, 95% CI: 1.30-6.08). CCSs whose cancers were diagnosed before age 5 versus 10-17 years showed significantly increased risks (HR = 2.38, 95% CI: 1.39-4.07). In this dose-adjusted model, volume was not significantly associated with increased risk (HR full vs partial = 1.66, 95% CI: 0.86-3.22). Overall, the ERR/Gy was 0.30 (95% CI: 0.03-unknown). Dose effects did not vary significantly according to exposure age or CrRT volume. Cumulative incidence after any CrRT was 12.4% (95% CI: 9.8%-15.2%) 40 years after primary cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only carboplatin (HR = 3.55, 95% CI: 1.62-7.78) appeared associated with meningioma risk. However, we saw no carboplatin dose-response and all 9 exposed cases had high-dose CrRT., Conclusion: After CrRT 1 in 8 survivors developed late meningioma by age 40 years, associated with radiation dose and exposure age, relevant for future treatment protocols and awareness among survivors and physicians., (© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results